Equity Investments for Which Measurement Alternative Has Been Selected	9 Months Ended
Sep. 30, 2024
Equity Investments For Which Measurement Alternative Has Been Selected
Equity Investments for Which Measurement Alternative Has Been Selected	8. Equity Investments for Which Measurement Alternative Has Been Selected As of September 30, 2024 and December 31, 2023, the Company held equity investments in other securities valued at $5.3 million and $21.8 million, respectively, that were valued using a measurement alternative. These investments are included in other equity securities in the accompanying consolidated balance sheets. The Company has made cumulative downward adjustments for impairments for equity securities that do not have readily determinable fair values for the nine months ended September 30, 2024 and 2023, totaling $6.3 million and $11.6 million, respectively. Approximately $6.3 million of the impairment charge for the nine months ended September 30, 2024 was reflected in other income (expense) on the condensed consolidated statement of operations and comprehensive loss. Approximately $9.6 million of the impairment charge for the nine months ended September 30, 2023 was reflected in other income (expense) and $2.0 million of the impairment charge related to Fintech lending operations and was recorded against revenue from lending and trading activities on the condensed consolidated statement of operations and comprehensive loss.

Equity Investments for Which Measurement Alternative Has Been Selected

9 Months Ended

Sep. 30, 2024

Equity Investments For Which Measurement Alternative Has Been Selected

Equity Investments for Which Measurement Alternative Has Been Selected

8. Equity Investments for Which Measurement Alternative Has Been Selected

As of September 30, 2024 and December 31, 2023, the Company held equity investments in other securities valued at $5.3 million and $21.8 million, respectively, that were valued using a measurement alternative. These investments are included in other equity securities in the accompanying consolidated balance sheets.

The Company has made cumulative downward adjustments for impairments for equity securities that do not have readily determinable fair values for the nine months ended September 30, 2024 and 2023, totaling $6.3 million and $11.6 million, respectively. Approximately $6.3 million of the impairment charge for the nine months ended September 30, 2024 was reflected in other income (expense) on the condensed consolidated statement of operations and comprehensive loss. Approximately $9.6 million of the impairment charge for the nine months ended September 30, 2023 was reflected in other income (expense) and $2.0 million of the impairment charge related to Fintech lending operations and was recorded against revenue from lending and trading activities on the condensed consolidated statement of operations and comprehensive loss.